scholarly journals Change in Body Weight and Serum Albumin Levels in Febrile Neutropenic Lung Cancer Patients

2020 ◽  
Vol 5 (3) ◽  
pp. 120-127
Author(s):  
Naomi Kayauchi ◽  
Yumi Nakagawa ◽  
Takako Oteki ◽  
Katsunori Kagohashi ◽  
Hiroaki Satoh
Keyword(s):  
Lung Cancer ◽  
Body Weight ◽  
Nutritional Status ◽  
Serum Albumin ◽  
Cancer Patients ◽  
Albumin Level ◽  
Cytotoxic Chemotherapy ◽  
Lung Cancer Patients ◽  
Treatment And Prevention ◽  
And Control

Although advances have been made in the treatment and prevention of febrile neutropenia (FN) in cancer patients treated with chemotherapy, it is still a complication that requires clinical attention. Impaired nutritional status in patients who develop FN can affect the continuation of cancer treatment, but it has not been investigated. We conducted a retrospective longitudinal study in order to clarify (1) if body weight and serum albumin levels change in lung cancer patients who do and do not develop FN, and (2) if these indicators are more likely to worsen in patients with FN than in patients without FN. Patients undergoing cytotoxic chemotherapy between January 2011 and June 2020 were consecutively included in the study. Changes in body weight and serum albumin levels were investigated in a case–control study of patients with FN, and control patients without FN who were matched by age, gender, histopathology, and stage of lung cancer, at a ratio of 1:2. During the study period, 226 patients received cytotoxic chemotherapy. Among those, 33 (14.6%) patients developed FN during the first course of cytotoxic chemotherapy. We found a more pronounced decrease in both body weight and serum albumin level at four weeks after the initiation of chemotherapy in FN patients. In order to safely administer effective chemotherapy, medical staff need to pay close attention to the nutritional status of patients receiving chemotherapy.

scholarly journals Higher Nutritional Status of Lung Cancer Cachexia Patients is Associated with Higher Functional Capacity and Appetite

2019 ◽  
Vol 2 (2) ◽  
pp. 32
Author(s):  
Diana Sunardi ◽  
Saptawati Bardosono
Keyword(s):  
Lung Cancer ◽  
Weight Loss ◽  
Body Weight ◽  
Serum Albumin ◽  
Cancer Patients ◽  
Functional Capacity ◽  
Negative Impact ◽  
Cross Sectional Study ◽  
Albumin Level ◽  
Cross Sectional

Introduction: Lung cancer is highly prevalent and the major cause of cancer-related deaths worldwide.  Severity of weight loss has been shown to have a negative impact on patients’ performance and quality of life.  Early detection of anorexia and decline of functional capacity will be very usefull to prevent severe weight loss and a better prognosis. Methods: A cross sectional study was conducted in Dharmais Cancer Hospital.  Subjects were lung cancer patients newly diagnosed or a minimal of 2 months pasca chemotherapy or radiotherapy, taken consecutively from inpatients and outpatients.  Results: Subjects eligible for the study were 47, with a composition of 55.3% men and 44.7% women in the age range from 36–79 years old. There were significant relationship between body weight and BMI with ECOG score. Body weight, BMI  and weight loss related significantly with VAS appetite and SNAQ score.  These result indicate that subjects with a higher BMI and a lower weight loss have a better physical performa and appetite.  There were significant relation between haemoglobin level, anemia status and serum albumin level with appetite and risk for anorexia. This result indicate that subjects with normal haemoglobin  and albumin have a good appetite and a lower risk for anorexia.  Conclusions: Positive prognosis of cancer patients can be obtained by maintaining BMI and preventing weight loss, since both affected the already known prognostic marker functional capacity significantly.  Serum Albumin and hemoglobin are not only simple test, but also brings benefits, a clinical marker that may be used to assess the risk of anorexia.

scholarly journals Integrative Treatment of Lung Cancer Patients: Observational Study of 57 Cases

2021 ◽  
Author(s):  
Lorenzo Anelli ◽  
Alessia Di Nardo ◽  
Massimo Bonucci
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Nutritional Status ◽  
Cancer Patients ◽  
Immune Status ◽  
Conventional Medicine ◽  
Integrative Therapy ◽  
Lung Cancer Patients ◽  
Retrospective Clinical Study

Abstract Introduction A retrospective clinical study was performed to identify the characteristics of patients with lung cancer treated with integrative cancer treatment in addition to conventional medicine. Materials and Methods We reviewed medical records for lung cancer patients who visited a single integrative setting in Rome, Italy. A total of 57 patients were included, and the majority had advanced-stage cancer. All of them underwent integrative therapy with nutrition and phytotherapy indications. The diet was designed to reduce most of possible factors promoting cancer proliferation, inflammation, and obesity. Foods with anti-inflammatory, prebiotic, antioxidant, and anticancer properties had been chosen. Herbal supplements with known effects on lung cancer were prescribed. In particular, astragal, apigenine, fucosterol, polydatin, epigallocatechin gallate, cannabis, curcumin, and inositol were used. Furthermore, medical mushrooms and other substances were used to improve the immune system and to reduce chemotherapy side effects. Five key parameters have been evaluated for 2 years starting at the first surgery: nutritional status, immune status, discontinuation of therapy, quality of life, and prognosis of the disease. Results A relevant improvement in parameters relative to nutritional status, immune status, and quality of life has been observed after integrative therapy compared with the same parameters at the first medical visit before starting such approach. Conclusion The results suggest that integrative therapy may have benefits in patients with lung cancer. Even though there are limitations, the study suggests that integrative therapy could improve nutritional status and quality of life, with possible positive effect on overall survival.

scholarly journals The Prevalence of Malnutrition in Patients Suffering from Different Cancers by Three Classification Methods (P05-041-19)

2019 ◽  
Vol 3 (Supplement_1) ◽  
Author(s):  
Wenzhi Zhao ◽  
Han Ping Shi
Keyword(s):  
Lung Cancer ◽  
Head And Neck Cancer ◽  
Serum Albumin ◽  
Cancer Patients ◽  
Gastrointestinal Cancer ◽  
Serum Albumin Level ◽  
Hematological Malignancy ◽  
Albumin Level ◽  
Baseline Survey ◽  
Classification Methods

Abstract Objectives The objective of this study was to determine the prevalence of malnutrition in hospitalized cancer patients. Methods A facility-based follow-up study was conducted in 84 hospitals across 25 provinces and municipalities from January 2011 to December 2018, during which the number of the involved hospital accumulated slowly. In this study the data of the baseline survey is extracted. The prevalence of malnutrition in hospitalized cancer patients is determined by three classification methods: body mass index (BMI, BMI < 18.5 kg/m2), serum albumin level (serum albumin <35 g/L) and Patient-Generated Subjective Global Assessment (PG-SGA, nutritional assessment of B or C level). Results 36,635 hospitalized patients with different kinds of cancer finished the baseline survey, of whom 54.6% were male and the mean age was 56.6 years old (ranging from 1 to 118.5 years old). On the whole, the prevalence of malnourished nutritional status determined by BMI, serum albumin level and PG-SGA was 12.0%, 20.6% and 80.0%, respectively. The consistent trend is that the prevalence is higher in the male and the old, patients of later-stage, patients with longer duration and patients with metastasis based on three different classification methods. When the cancers were classified into 6 categories, that is lung cancer, head and neck cancer, gastrointestinal cancer, hematological malignancy, urogenital neoplasm and other tumors, the prevalence was highest in gastrointestinal cancer patients, and the prevalence was 16.4%, 26.1% and 87.6% assessed by three methods. While the prevalence in lung cancer patients was 9.3%, 20.7% and 79.4%, in urogenital neoplasm patients was 6.5%, 11.7% and 70.2%, in hematological malignancy patients was 9.2%, 24.6% and 79.1%, in hematological malignancy patients was 9.2%, 24.6% and 79.1% and in patients of head and neck cancer was 11.0%, 9.3% and 62.3%. Conclusions The data showed the high prevalence of malnutrition in hospitalized cancer patients in China in this study. The prevalence of malnutrition in different cancers differed a lot and was highest in gastrointestinal cancer patients. Funding Sources The National Key Research and Development Program of China.

Beneficial effects of ATP on body weight and muscle strength in lung cancer patients

1999 ◽  
Vol 11 (12) ◽  
pp. A25
Author(s):  
H. J. Agteresch ◽  
P. C. Dagnelie ◽  
J. W.O. van den Berg ◽  
J. H.P. Wilson
Keyword(s):  
Lung Cancer ◽  
Body Weight ◽  
Muscle Strength ◽  
Cancer Patients ◽  
Lung Cancer Patients ◽  
Beneficial Effects

Assessment of PD-L1 expression and oncogenic gene status in patients with small-cell lung cancer: Immuno-oncology biomarker study in LC-SCRUM-Japan.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. 8558-8558
Author(s):  
Satoshi Oizumi ◽  
Kiyotaka Yoh ◽  
Shingo Matsumoto ◽  
Shingo Miyamoto ◽  
Naoki Furuya ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Cytotoxic Chemotherapy ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Patients ◽  
Gene Status ◽  
Oncogenic Gene

8558 Background: The clinical impact of PD-L1 expression and oncogenic gene status in patients with small cell lung cancer (SCLC) is not well characterized. We initiated this immuno-oncology biomarker study as part of nationwide genomic screening by LC-SCRUM-Japan (LC-SCRUM-IBIS). Methods: Tumor samples from lung cancer patients enrolled in LC-SCRUM-IBIS were primarily subjected to targeted next-generation sequencing (NGS) with Oncomine™ Comprehensive Assay. The PD-L1 expression was also analyzed by 4 immunohistochemistry (IHC) assays for 22C3, 28-8, SP263 and SP142. At this analysis, 22C3, 28-8, and SP263 were assessed in tumor cells (TC) as positive in > 1%, and SP142 in both TC and tumor-infiltrating immune cells (IC) as positive in > TC1/IC1, as previously reported. The association of PD-L1 expression, oncogenic gene status and clinical outcome was investigated in SCLC patients. Results: Between Feb 2017 and May 2018, 1017 lung cancer patients were enrolled in LC-SCRUM-IBIS. Among them, 933 patients had adequate tumor samples including 101 SCLC and 832 non-small cell lung cancer. Of 101 SCLC patients, the results of PD-L1 expression by 4 IHC assays were 18% in 22C3, 17% in 28-8, 11% in SP263 and 8% in SP142, respectively. Targeted NGS showed that 8 patients had at least one targetable oncogenic alterations, including 3 PIK3CA and 1 KRAS as mutations and 3 PTEN and 1 TSC2 as inactivating mutations. PD-L1 expression by 22C3 was associated with good performance status (P = 0.05) and the presence of oncogenic alterations (P = 0.004). PD-L1 status was not associated with response to cytotoxic chemotherapy and progression-free survival and overall survival in first-line treatment of SCLC patients. Conclusions: The frequency of PD-L1 expression in SCLC patients was relatively lower compared with that reported in other solid tumors. PD-L1 status by TC in 22C3 appears to be not correlated with clinical outcomes for cytotoxic chemotherapy of SCLC patients. Further investigation is needed to explore a predictive biomarker for immune checkpoint inhibitors. Updated results will be presented at the meeting.

Sign in / Sign up

Export Citation Format

Share Document